Difluorocarbene radiosynthesis
US-2024383827-A1 · Nov 21, 2024 · US
US9957225B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9957225-B2 |
| Application number | US-201414480899-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 9, 2014 |
| Priority date | Nov 11, 2005 |
| Publication date | May 1, 2018 |
| Grant date | May 1, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides methods of treating Friedreich's ataxia and other neurodegenerative or neuromuscular conditions using histone deacetylase inhibitors.
Opening claim text (preview).
What is claimed is: 1. A method of treating, or delaying the onset of Huntington's disease in a mammal comprising administering to the mammal a compound of formula I in an amount effective to alter the level of histone acetylation in the mammal and increase frataxin mRNA in lymphocytes from Friedreich's ataxia patients, wherein formula I is: wherein: n is 2 to about 10; R 1 is aryl or heteroaryl; R 2 is aryl or heteroaryl; R a and R b are each independently H, alkyl, aryl, heteroaryl, or a nitrogen protecting group; wherein any alkyl, aryl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of hydroxy, amino, nitro, cyano, halo, alkyl, trifluoromethyl, alkoxy, aryl, and NR c R d ; wherein R c and R d are each independently hydrogen, alkyl, or C(═O)OR e wherein R e is H or alkyl; or a salt thereof. 2. The method of claim 1 , further comprising identifying the mammal as one suffering from, or at risk for, Huntington's disease. 3. The method of claim 1 , wherein the mammal is a human. 4. The method of claim 1 , wherein the compound of formula I has a structure selected from the group consisting of: a salt of a compound thereof; and any combination thereof.
having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton · CPC title
having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings · CPC title
from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines · CPC title
having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title
Preparation of carboxylic acid amides · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.